Gradalis, Inc.
Records under this name other than the patents Gradalis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,290,763 | Construction of bifunctional short hairpin RNA Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,556,431 | ShRNA molecules and methods of use thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,683,237 | Multiple Targeted Rnai for the Treatment of Cancers Formerly held Lapsed on the fee record Ended Jun 20, 2025 · Medium confidence | Lapsed on the fee record | Ended Jun 20, 2025 | Medium confidence |
| US 8,460,908 | Polypeptides Having Colanic Acid-Degrading Activity Lapsed on the fee record Ended Jun 11, 2025 · High confidence | Lapsed on the fee record | Ended Jun 11, 2025 | High confidence |
| US 9,562,023 | Dipeptide mimics, libraries combining two dipeptide mimics with a third group, and methods for production thereof Lapsed on the fee record Ended Feb 7, 2025 · From the USPTO record | Lapsed on the fee record | Ended Feb 7, 2025 | From the USPTO record |
| US 8,361,983 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors Lapsed on the fee record Ended Jan 29, 2021 · High confidence | Lapsed on the fee record | Ended Jan 29, 2021 | High confidence |
| US 8,333,988 | Targeted delivery using tissue-specific peptidomimetic ligands Lapsed on the fee record Ended Dec 18, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 18, 2020 | From the USPTO record |
| US 9,273,300 | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy Formerly held Lapsed on the fee record Ended Mar 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 1, 2020 | From the USPTO record |
| US 9,133,459 | Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors Lapsed on the fee record Ended Sep 15, 2019 · High confidence | Lapsed on the fee record | Ended Sep 15, 2019 | High confidence |
| US 8,969,068 | Processes for the Preparation of Highly Pure Plasmid Compositions by Enzymatic Digestion of Colanic Acid Lapsed on the fee record Ended Mar 3, 2019 · High confidence | Lapsed on the fee record | Ended Mar 3, 2019 | High confidence |